Scope: Comprehensive review of ANGPTL3 inhibition as a therapeutic strategy to reduce triglyceride-rich lipoproteins and residual cardiovascular risk Therapeutic approaches discussed: Monoclonal antibodies (e.g., evinacumab) RNA-based therapies (ASOs and siRNA: vupanorsen, zodasiran, solbinsiran) Emerging gene-editing strategies (CRISPR/base editing) Key message: Targeting ANGPTL3 provides robust reductions in triglycerides, apoB-containing lipoproteins, and non-HDL cholesterol, independently of the LDL receptor Clinical relevance: Positions ANGPTL3 inhibition as a next-generation approach for managing mixed dyslipidemia and lipid-related residual risk beyond LDL-C Laura Schreier Natalia Nardelli European Atherosclerosis Society To view or add a comment, sign in Tipping the Scale in MASH: The TZD vs
In some cases, slowed intestinal motility may lead to small intestinal bacterial overgrowth (SIBO), further contributing to bloating and gas
After joining our weight loss program in Missouri City, Texas, you can expect to speak to a board-certified physician or provider about your weight loss goals
But if the scale has been genuinely flat for three to four consecutive weeks and your habits havent changed, the dose may simply not be generating enough of a deficit to keep things moving
